Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Haemonetics Corp (NYSE: HAE) closed at $75.24 up 2.38% from its previous closing price of $73.49. In other words, the price has increased by $2.38 from its previous closing price. On the day, 0.57 million shares were traded. HAE stock price reached its highest trading level at $75.88 during the session, while it also had its lowest trading level at $73.76.
Ratios:
For a deeper understanding of Haemonetics Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 99.76. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 3.49. In the meantime, Its Debt-to-Equity ratio is 1.39 whereas as Long-Term Debt/Eq ratio is at 1.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on December 06, 2024, initiated with a Overweight rating and assigned the stock a target price of $116.
On November 08, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $120.
On September 13, 2024, CL King started tracking the stock assigning a Buy rating and target price of $116.CL King initiated its Buy rating on September 13, 2024, with a $116 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 11 ’24 when Lingamneni Anila bought 6,238 shares for $90.68 per share.
Strong Stewart W sold 4,312 shares of HAE for $393,039 on Jul 26 ’24. The President, Global Hospital now owns 18,196 shares after completing the transaction at $91.15 per share. On Jul 26 ’24, another insider, Strong Stewart W, who serves as the Officer of the company, bought 4,312 shares for $91.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3778846208 and an Enterprise Value of 4793786368. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.25, and their Forward P/E ratio for the next fiscal year is 14.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 4.31. Its current Enterprise Value per Revenue stands at 3.522 whereas that against EBITDA is 15.259.
Stock Price History:
Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $69.29. The 50-Day Moving Average of the stock is -8.45%, while the 200-Day Moving Average is calculated to be -8.95%.
Shares Statistics:
For the past three months, HAE has traded an average of 578.42K shares per day and 526270 over the past ten days. A total of 50.38M shares are outstanding, with a floating share count of 49.67M. Insiders hold about 1.11% of the company’s shares, while institutions hold 112.10% stake in the company. Shares short for HAE as of 1735603200 were 5229686 with a Short Ratio of 9.04, compared to 1732838400 on 4567100. Therefore, it implies a Short% of Shares Outstanding of 5229686 and a Short% of Float of 16.469998999999998.
Earnings Estimates
The stock of Haemonetics Corp (HAE) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $1.29, with high estimates of $1.33 and low estimates of $1.25.
Analysts are recommending an EPS of between $4.62 and $4.55 for the fiscal current year, implying an average EPS of $4.59. EPS for the following year is $5.28, with 10.0 analysts recommending between $5.45 and $5.04.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $352.88M this quarter.It ranges from a high estimate of $355.09M to a low estimate of $349M. As of the current estimate, Haemonetics Corp’s year-ago sales were $336.25MFor the next quarter, 10 analysts are estimating revenue of $359.02M. There is a high estimate of $364.4M for the next quarter, whereas the lowest estimate is $352.63M.
A total of 10 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.4B, while the lowest revenue estimate was $1.39B, resulting in an average revenue estimate of $1.39B. In the same quarter a year ago, actual revenue was $1.31BBased on 10 analysts’ estimates, the company’s revenue will be $1.44B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.4B.
